TechCrunch reporter Devin Coldewey spotlights how MIT researchers have developed a machine learning technique for proposing new molecules for drug discovery that ensures suggested molecules can be synthesized in a lab. Coldewey also features how MIT scientists created a new method aimed at teaching robots how to interact with everyday objects.
MIT researchers have developed a new technique that uses deep learning to improve the process of drug discovery, reports Jonathan Vanian for Fortune. “The technique addresses a common problem that researchers face when using A.I. to develop novel molecular structures: life sciences experts can often face challenges synthesizing A.I.-created molecular structures,” writes Vanian.
Bloomberg Businessweek reporter Peter Coy spotlights how the loss of several people close to Prof. Andrew Lo inspired him to explore how the field of finance could help advance treatments for orphan diseases. “Finance plays a huge role, sometimes way too big a role, in how drugs get developed,” says Lo. Fixing the financing model, could have a “tremendous, tremendous impact on health care.”
CNBC reporter Charlie Wood features tProf. Connor Coley's work developing a new system that could be used to help automate molecule manufacturing. “It tries to understand, based on those patterns, what kind of transformations should work for new molecules it’s never seen before,” says Coley.
Tech Explorist reporter Amit Malewar writes that researchers from Singapore-MIT Alliance for Research and Technology (SMART) have “demonstrated a new way to manufacture human red blood cells (RBCs) that cuts the culture time by half compared to existing methods.”
On this episode of Freakonomics, Prof. Andrew Lo discusses the economics of drug development. “It’s important that we get the pricing of these vaccines correct so that they provide both a reasonable rate of return to investors who have risked their capital to develop these vaccines, while at the same time making sure that there’s no price gouging going on and that ultimately we provide access to everybody,” says Lo.
Writing for The New Yorker, Bernard Avishai spotlights Prof. Andrew Lo’s work exploring the need for a revolution in financial engineering to help spur the development of vaccines, and how a vaccine megafund could have assisted in bringing the Covid-19 pandemic under control. “The more I studied this, the more I realized that finance actually plays a huge role in drug development,” says Lo, “in many cases, way too big a role.”
Writing for Science, Derek Lowe spotlights how MIT researchers are developing a platform that could be used to automate the production of molecules for use in medicine, solar energy and more. “The eventual hope is to unite the software and the hardware in this area,” reports Lowe, “and come up with a system that can produce new compounds with a minimum of human intervention.”
MIT researchers have engineered wasp venom to kill bacteria, reports Chukwuma Muanya for The Guardian. The researchers found that the altered peptides wiped out the antibiotic-resistant bacteria Pseudomonas aeruginosa within four days.
Forbes reporter Fiona McMillan writes that MIT researchers have engineered an anti-bacterial peptide found in wasp venom in an effort to create a new antibiotic. McMillan writes that the researchers, “gained new insight into which structural attributes work best, either alone or in combination. In this way, they were able to tweak the peptide’s structure to obtain optimal function.”
MIT researchers have repurposed the toxic venom found in wasps to create a new drug that could potentially be used to kill bacteria, reports the Xinhua news agency. “The venom-derived peptide is believed to kill microbes by disrupting bacterial cell membranes,” Xinhua explains.
Boston Herald reporter Jordan Graham writes that MIT researchers have used the venom from a South American wasp to engineer a new type of antibiotic. “The idea here is to take that very well-crafted toxin and turn it into something that can be useful for humans and our society,” explains César de la Fuente Nunez, a postdoc at MIT.
Prof. Linda Griffith speaks with Hari Sreenivasan of PBS NewsHour about her work developing a new “body on a chip” that could allow researchers to test new drugs on organ tissue. Griffith explains that the device models how different organs and cells communicate in the human body, which is “really important for things like arthritis, Alzheimer's, where you've got multiple organs involved.”
Prof. Linda Griffith speaks with Wall Street Journal reporter Mark Ellwood about her work developing a new device that allows researchers to test how a drug affects the human body. Ellwood notes that the technology that Griffith and her team have created “could prove vital for rapidly releasing new vaccines.”
A team of researchers led by Prof. J. Christopher Love has developed a system to produce on-demand clinical-grade vaccines and drugs, writes Dr. Francis Collins on the NIH Director’s Blog. In addition to allowing on site production for hospitals the systems could also “produce biologic treatments specially tailored to attack the cancer of a particular individual,” suggests Collins.